Grape King Bio Ltd (TPE:1707)
129.50
+0.50 (0.39%)
Sep 1, 2025, 9:55 AM CST
Grape King Bio Revenue
Grape King Bio had revenue of 2.57B TWD in the quarter ending June 30, 2025, a decrease of -6.86%. This brings the company's revenue in the last twelve months to 10.88B, up 0.17% year-over-year. In the year 2024, Grape King Bio had annual revenue of 11.16B with 4.93% growth.
Revenue (ttm)
10.88B
Revenue Growth
+0.17%
P/S Ratio
1.76
Revenue / Employee
21.71M
Employees
501
Market Cap
19.11B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 11.16B | 524.54M | 4.93% |
Dec 31, 2023 | 10.64B | 244.23M | 2.35% |
Dec 31, 2022 | 10.39B | 592.99M | 6.05% |
Dec 31, 2021 | 9.80B | 630.05M | 6.87% |
Dec 31, 2020 | 9.17B | -70.88M | -0.77% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Caliway Biopharmaceuticals | 44.83M |
PharmaEssentia | 12.63B |
Bora Pharmaceuticals Co., LTD. | 21.32B |
Lotus Pharmaceutical | 19.12B |
Oneness Biotech | 112.57M |
Lumosa Therapeutics | 37.25M |
Polaris Group | 87.67M |
Center Laboratories | 1.60B |